Bazedoxifene

Amid ongoing approaches to lower drug prices for US patients, like the Most-Favored-Nation policy, this is another partnership the Trump Administration believes will improve access challenges. The Trump Administration is set to team up with Pfizer in a partnership that would bring lower prices for the manufacturer’s drugs as well as a direct-to-consumer (DTC) website for patients to purchase them, which the White House is naming “TrumpRx.”1 While the rollout of this new partnership is still in its beginning stages, Pfizer is the first drugmaker to provide actionable steps in lowering US drug prices across the board,2 an initiative perpetuated by the signing of the Most-Favored-Nation (MFN) Prescription Drug Pricing Executive Order.3 “It’s a win for American patients, a win for American leadership, and it’s a win for Pfizer because it provides the certainty and stability we need to continue advancing new breakthrough medicines for patients,” said Pfizer spokeswoman Amy Rose, according to The Wall Street Journal.2 Despite early reports of the Pfizer program providing a decrease in drug prices for Medicaid patients, there is potential for savings to reach the pockets of all US patients and consumers as President Trump continues to put pressure on manufacturers. On top of this most recent Pfizer-White House partnership, as well as provisions backed by the MFN policy, the potential impact of pharmaceutical tariffs could add a third layer to the evolution of drug prices in the US. With the new partnership, Pfizer will receive a 3-year grace period on being susceptible to Trump’s pharmaceutical tariffs, which are expected to take effect October 1. “The agreement on lower prices will cover ‘a large majority’ of Pfizer's primary care medicines, along with specialty brand-name drugs, which will be offered at discounts averaging 50% and reaching as high as 85%, a spokesperson for the company said,” according to NBC News.1 Some of the drugs correspondents close to the partnership have named for future price reductions include the menopause medication Duavee (conjugated estrogens/bazedoxifene), Toviaz (fesoterodine fumarate) for treating overactive bladder, and Pfizer’s Eucrisa (crisaborole) skin ointment.4-6 On top of these, and whatever additional drugs that Pfizer already markets, all new drugs that the company introduces will also be sold at lower prices.1 Alongside the announcement of this unprecedented partnership, the administration is set to roll out its “TrumpRx” DTC website for patients across the country to access necessary prescription medications. The website will be fully owned and operated by the US government as well as giving it the federal power to negotiate the prices of DTC drugs themselves.2 The extent of which drugs will be offered and at what type of discounts through the TrumpRx website is currently unknown. There is also uncertainty regarding what patient populations and insurance coverage would be set aside to reap the benefits of these discounts and savings. However, according to Pfizer and White House spokespeople who reported to The Wall Street Journal, the new partnership is projected to benefit as many as 100 million US patients. “Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations,” said Trump, according to Politico.7 Amid the administration’s ongoing commitment to lower US drug prices, they are looking to get US consumers on a level playing field with consumers in other, developed nations. Hence, the MFN drug policy; this was signed as an executive order in June of this year and plainly states that multiple federal agencies should “take specific actions aimed at compelling drug manufacturers to lower drug prices in the United States in a manner comparable with other ‘developed nations.’”3 From the MFN drug policy to prospective pharmaceutical tariffs and a key partnership between the federal government and a major US drug manufacturer, there is significant movement from the Trump Administration to recorrect the rate of rising drug costs in the US. Many experts in the pharmacy and pharmaceutical industry have expressed disagreement and uncertainty regarding the aforementioned provisions, partnerships, and policies. However, with the continued fight stemming from the administration’s goal to lower drug prices, patients can be hopeful for discounted savings as these programs roll out.1 “President Trump is leveraging the power of the federal government to drastically cut drug prices for everyday Americans,” concluded White House spokesman Kush Desai, according to The Wall Street Journal.2 “Democrats talked the talk for decades about drug prices, but only President Trump is actually walking the walk.” The content above comes from the network. if any infringement, please contact us to modify.

A press conference was held in the Oval Office to announce the deal between Pfizer and the US Government. Image credit: Win McNamee / Staff via Getty Images. Pfizer is the first in what could be a string of pharmaceutical companies to come to an agreement with the White House to reduce US drug prices. As part of President Trump’s Most Favored Nation (MFN) policy , the company agreed to ensure that US patients are paying less for prescription medicines, with primary care treatments and some select speciality brands set to be offered at savings that will range as high as 85% and an average of 50%. The MFN policy has been set up by Trump’s administration to tie drug prices in the US to those paid elsewhere in the world. These savings will be accessible through both Medicaid and the federal direct purchasing platform TrumpRx.gov. It was also announced that all new medications from Pfizer will be sold at MFN levels. In a 30 September press conference, Trump said: “For many years, Americans have paid the highest prices anywhere in the world for prescription drugs. The major reason is that American consumers have been subsidising research and development costs for the entire planet. They put all of that on us, and yet they were the beneficiaries, so that is being changed as of today.” Discounts, shown on a poster during the press conference, include an 80% discount on Eucrisa (crisaborole), an 85% discount on Duavee (conjugated estrogens/bazedoxifene), 50% off Zavzpret (zavegepant), and 40% off Xeljanz (tofacitinib). GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The agreement includes a three-year grace period that excludes Pfizer from facing tariffs, as long as the promised $70bn investment into US manufacturing goes ahead. In the press conference, Pfizer CEO Albert Bourla said: “This is a historic day – we are turning the tide and reversing an unfair situation. For years, other rich nations have refused to pay their fair share for medical innovation. This is changing today with this agreement.” While Pfizer is the first to have come to this agreement with the US Government, Trump said that agreements with other pharmaceutical companies could happen in the next few weeks. GlobalData research analyst Cyrus Fan said: “The Trump administration has said the Pfizer deal is the first in a series of deals it intends to secure for the US. This implies more companies will agree to MFN pricing. It is also clear that the Trump administration is easing implementation of MFN by introducing IRP in Medicaid first, leaving room for expansion in the future.” GlobalData is the parent company of Clinical Trials Arena. For those who do not agree to increase the US manufacturing presence and make price agreements with the federal government, President Trump has threatened a 100% tariff on pharmaceutical goods. In a post on his social media network, TruthSocial, on 25 September, President Trump said: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. ‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.” This all comes amid a potential government shutdown, with Democrats accusing the Republicans of approving cuts to the Medicaid programme and other health safety nets that could leave millions of US citizens uninsured in the next ten years. Editor’s note: Comments from GlobalData analyst Cyrus Fan have been added. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now